FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:2239-2246 May 27, 2004 Number 22 Next

Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level 4.0 ng per Milliliter

	Full Text PDF PDA Full Text Editorial by Carter, H. B. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background The optimal upper limit of the normal range for prostate-specific antigen (PSA) is unknown. We investigated the prevalence of prostate cancer among men in the Prostate Cancer Prevention Trial who had a PSA level of 4.0 ng per milliliter or less.

Methods Of 18,882 men enrolled in the prevention trial, 9459 were randomly assigned to receive placebo and had an annual measurement of PSA and a digital rectal examination. Among these 9459 men, 2950 men never had a PSA level of more than 4.0 ng per milliliter or an abnormal digital rectal examination, had a final PSA determination, and underwent a prostate biopsy after being in the study for seven years.

Results Among the 2950 men (age range, 62 to 91 years), prostate cancer was diagnosed in 449 (15.2 percent); 67 of these 449 cancers (14.9 percent) had a Gleason score of 7 or higher. The prevalence of prostate cancer was 6.6 percent among men with a PSA level of up to 0.5 ng per milliliter, 10.1 percent among those with values of 0.6 to 1.0 ng per milliliter, 17.0 percent among those with values of 1.1 to 2.0 ng per milliliter, 23.9 percent among those with values of 2.1 to 3.0 ng per milliliter, and 26.9 percent among those with values of 3.1 to 4.0 ng per milliliter. The prevalence of high-grade cancers increased from 12.5 percent of cancers associated with a PSA level of 0.5 ng per milliliter or less to 25.0 percent of cancers associated with a PSA level of 3.1 to 4.0 ng per milliliter.

Conclusions Biopsy-detected prostate cancer, including high-grade cancers, is not rare among men with PSA levels of 4.0 ng per milliliter or less — levels generally thought to be in the normal range.

Source Information

From the Division of Urology, Department of Surgery, University of Texas Health Science Center at San Antonio, San Antonio (I.M.T.); the Fred Hutchinson Cancer Research Center, Seattle (D.K.P., P.J.G., C.M.T.); the University of Colorado Health Science Center, Denver (M.S.L., E.D.C.); the Division of Cancer Prevention, National Cancer Institute, Bethesda, Md. (H.L.P., L.M.M., L.G.F.); the Department of Clinical Cancer Prevention, M.D. Anderson Cancer Center, Houston (S.M.L.); Cancer Research and Biostatistics, Seattle (J.J.C.); and the Southwest Oncology Group, San Antonio, Tex. (C.A.C.).

Address reprint requests to the Southwest Oncology Group (SWOG-9217), Operations Office, 14980 Omicron Dr., San Antonio, TX 78245-3217.

Full Text of this Article

Related Letters:

Prostate Cancer with Low PSA Levels
Beatty P. A., Glaser A. I., Rocco B., Matei D. V., de Cobelli O., Datta M. W., Berman J. J., Dhir R.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:1802-1803, Oct 21, 2004. Correspondence

This article has been cited by other articles:

• Lilja, H. (2008). Testing New PSA Subforms to Enhance the Accuracy of Predicting Cancer Risk and Disease Outcome in Prostate Cancer. Clin. Chem. 54: 1248-1249 [Full Text]  
• McFall, S. L., Ureda, J., Byrd, T. L., Valdes, A., Morales, P., Scott, D. B., Williams, D., Calderon-Mora, J., Casillas, M. E., Chan, E. C. Y. (2008). What is needed for informed decisions about prostate cancer screening: perspectives of African-American and Hispanic men. Health Educ Res 0: cyn018v1-cyn018 [Abstract] [Full Text]  
• Leeming, D. J., Hegele, A., Byrjalsen, I., Hofmann, R., Qvist, P., Karsdal, M. A., Schrader, A. J., Wagner, R., Olbert, P. (2008). Biochemical Markers for Monitoring Response to Therapy: Evidence for Higher Bone Specificity by a Novel Marker Compared with Routine Markers. Cancer Epidemiol. Biomarkers Prev. 17: 1269-1276 [Abstract] [Full Text]  
• Eekers, D. B. P., Laschet, A., de Groot, M., Roelofs, E., Kester, A., Delaere, K., Lambin, P., van Gils, F., Nap, M., ten Kate, J. (2008). Why determine only the total prostate-specific antigen, if the free-to-total ratio contains the information?. Ann Clin Biochem 45: 270-274 [Abstract] [Full Text]  
• Vener, T., Derecho, C., Baden, J., Wang, H., Rajpurohit, Y., Skelton, J., Mehrotra, J., Varde, S., Chowdary, D., Stallings, W., Leibovich, B., Robin, H., Pelzer, A., Schafer, G., Auprich, M., Mannweiler, S., Amersdorfer, P., Mazumder, A. (2008). Development of a Multiplexed Urine Assay for Prostate Cancer Diagnosis. Clin. Chem. 54: 874-882 [Abstract] [Full Text]  
• Kelly, K. A., Setlur, S. R., Ross, R., Anbazhagan, R., Waterman, P., Rubin, M. A., Weissleder, R. (2008). Detection of Early Prostate Cancer Using a Hepsin-Targeted Imaging Agent. Cancer Res. 68: 2286-2291 [Abstract] [Full Text]  
• Loeb, S., Catalona, W. J. (2008). What to Do with an Abnormal PSA Test. The Oncologist 13: 299-305 [Abstract] [Full Text]  
• Crawford, E. D. (2008). Response. JNCI J Natl Cancer Inst 100: 223-224 [Full Text]  
• Laxman, B., Morris, D. S., Yu, J., Siddiqui, J., Cao, J., Mehra, R., Lonigro, R. J., Tsodikov, A., Wei, J. T., Tomlins, S. A., Chinnaiyan, A. M. (2008). A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer. Cancer Res. 68: 645-649 [Abstract] [Full Text]  
• Connolly, D., Black, A., Gavin, A., Keane, P. F., Murray, L. J. (2008). Baseline Prostate-Specific Antigen Level and Risk of Prostate Cancer and Prostate-Specific Mortality: Diagnosis Is Dependent on the Intensity of Investigation. Cancer Epidemiol. Biomarkers Prev. 17: 271-278 [Abstract] [Full Text]  
• McLerran, D., Grizzle, W. E., Feng, Z., Bigbee, W. L., Banez, L. L., Cazares, L. H., Chan, D. W., Diaz, J., Izbicka, E., Kagan, J., Malehorn, D. E., Malik, G., Oelschlager, D., Partin, A., Randolph, T., Rosenzweig, N., Srivastava, S., Srivastava, S., Thompson, I. M., Thornquist, M., Troyer, D., Yasui, Y., Zhang, Z., Zhu, L., Semmes, O. J. (2008). Analytical Validation of Serum Proteomic Profiling for Diagnosis of Prostate Cancer: Sources of Sample Bias. Clin. Chem. 54: 44-52 [Abstract] [Full Text]  
• McLerran, D., Grizzle, W. E., Feng, Z., Thompson, I. M., Bigbee, W. L., Cazares, L. H., Chan, D. W., Dahlgren, J., Diaz, J., Kagan, J., Lin, D. W., Malik, G., Oelschlager, D., Partin, A., Randolph, T. W., Sokoll, L., Srivastava, S., Srivastava, S., Thornquist, M., Troyer, D., Wright, G. L., Zhang, Z., Zhu, L., Semmes, O. J. (2008). SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer. Clin. Chem. 54: 53-60 [Abstract] [Full Text]  
• Lane, J A., Howson, J., Donovan, J. L, Goepel, J. R, Dedman, D. J, Down, L., Turner, E. L, Neal, D. E, Hamdy, F. C (2007). Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. BMJ 335: 1139-1139 [Abstract] [Full Text]  
• Shim, H. B., Lee, S. E., Park, H. K., Ku, J. H. (2007). Histological Diagnosis of Prostate Cancer in Korean Men Aged 70 79 Years. Jpn J Clin Oncol 0: hym093v1-6 [Abstract] [Full Text]  
• Parekh, D. J., Ankerst, D. P., Baillargeon, J., Higgins, B., Platz, E. A., Troyer, D., Hernandez, J., Leach, R. J., Lokshin, A., Thompson, I. M. (2007). Assessment of 54 Biomarkers for Biopsy-Detectable Prostate Cancer. Cancer Epidemiol. Biomarkers Prev. 16: 1966-1972 [Abstract] [Full Text]  
• Kundra, V., Silverman, P. M., Matin, S. F., Choi, H. (2007). Imaging in Oncology from The University of Texas M. D. Anderson Cancer Center: Diagnosis, Staging, and Surveillance of Prostate Cancer. Am. J. Roentgenol. 189: 830-844 [Abstract] [Full Text]  
• BANYARD, J., HUTCHINSON, L. M., ZETTER, B. R. (2007). Thymosin beta-NB Is the Human Isoform of Rat Thymosin beta15. Ann. N. Y. Acad. Sci. 1112: 286-296 [Abstract] [Full Text]  
• Nam, R. K., Toi, A., Klotz, L. H., Trachtenberg, J., Jewett, M. A.S., Appu, S., Loblaw, D. A., Sugar, L., Narod, S. A., Kattan, M. W. (2007). Assessing Individual Risk for Prostate Cancer. JCO 25: 3582-3588 [Abstract] [Full Text]  
• Thompson, I. M., Pauler Ankerst, D., Chi, C., Goodman, P. J., Tangen, C. M., Lippman, S. M., Lucia, M. S., Parnes, H. L., Coltman, C. A. Jr (2007). Prediction of Prostate Cancer for Patients Receiving Finasteride: Results From the Prostate Cancer Prevention Trial. JCO 25: 3076-3081 [Abstract] [Full Text]  
• Kerfoot, B. P., Holmberg, E. F., Lawler, E. V., Krupat, E., Conlin, P. R. (2007). Practitioner-Level Determinants of Inappropriate Prostate-Specific Antigen Screening. Arch Intern Med 167: 1367-1372 [Abstract] [Full Text]  
• Fradet, Y. (2007). Rebuttal: Should Canadians be offered systematic prostate cancer screening?: YES. cfp 53: 1140-1141 [Full Text]  
• Fradet, Y. (2007). Refutation: Devrait-on offrir aux Canadiens le depistage systematique du cancer de la prostate?: OUI. cfp 53: 1142-1143 [Full Text]  
• Jewett, M. A.S., Klotz, L. H., for the University of Toronto Uro-Oncology Program, (2007). Advances in the medical management of benign prostatic hyperplasia. CMAJ 176: 1850-1851 [Full Text]  
• Freedland, S. J., Platz, E. A. (2007). Obesity and Prostate Cancer: Making Sense out of Apparently Conflicting Data. Epidemiol Rev 0: mxm006v1- [Abstract] [Full Text]  
• Martin, R. M (2007). Commentary: Prostate cancer is omnipresent, but should we screen for it?. Int J Epidemiol 36: 278-281 [Full Text]  
• Albertsen, P. C (2007). Commentary: Occult prostate cancer--imposter or the real deal?. Int J Epidemiol 36: 281-282 [Full Text]  
• Gross, M., Top, I., Laux, I., Katz, J., Curran, J., Tindell, C., Agus, D. (2007). {beta}-2-Microglobulin Is an Androgen-Regulated Secreted Protein Elevated in Serum of Patients with Advanced Prostate Cancer. Clin. Cancer Res. 13: 1979-1986 [Abstract] [Full Text]  
• Etzioni, R. D., Ankerst, D. P., Thompson, I. M. (2007). Re: Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability. JNCI J Natl Cancer Inst 99: 489-490 [Full Text]  
• Krist, A. H., Woolf, S. H., Johnson, R. E., Kerns, J. W. (2007). Patient Education on Prostate Cancer Screening and Involvement in Decision Making. Ann Fam Med 5: 112-119 [Abstract] [Full Text]  
• Bai, V. U., Kaseb, A., Tejwani, S., Divine, G. W., Barrack, E. R., Menon, M., Pardee, A. B., Reddy, G. P.-V. (2007). Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. Proc. Natl. Acad. Sci. USA 104: 2343-2348 [Abstract] [Full Text]  
• Lilja, H., Ulmert, D., Bjork, T., Becker, C., Serio, A. M., Nilsson, J.-A., Abrahamsson, P.-A., Vickers, A. J., Berglund, G. (2007). Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 Years. JCO 25: 431-436 [Abstract] [Full Text]  
• Werny, D. M., Thompson, T., Saraiya, M., Freedman, D., Kottiri, B. J., German, R. R., Wener, M. (2007). Obesity Is Negatively Associated with Prostate-Specific Antigen in U.S. Men, 2001-2004. Cancer Epidemiol. Biomarkers Prev. 16: 70-76 [Abstract] [Full Text]  
• Wilt, T. J, Thompson, I. M (2006). Clinically localised prostate cancer. BMJ 333: 1102-1106 [Full Text]  
• Thompson, I. M. (2006). PSA: A Biomarker for Disease. A Biomarker for Clinical Trials. How Useful Is It?. J. Nutr. 136: 2704S-2704S [Full Text]  
• Thomas, S., Chigurupati, S., Anbalagan, M., Shah, G. (2006). Calcitonin Increases Tumorigenicity of Prostate Cancer Cells: Evidence for the Role of Protein Kinase A and Urokinase-Type Plasminogen Receptor. Mol. Endocrinol. 20: 1894-1911 [Abstract] [Full Text]  
• Lee, S. E., Byun, S.-S., Park, H. K., Shim, H. B., Ku, J. H. (2006). Detection of Prostate Cancer at Low and Intermediate Serum Prostate-Specific Antigen Levels in a Country with a Low Incidence of Prostate Cancer. Jpn J Clin Oncol 36: 376-380 [Abstract] [Full Text]  
• Groskopf, J., Aubin, S. M.J., Deras, I. L., Blase, A., Bodrug, S., Clark, C., Brentano, S., Mathis, J., Pham, J., Meyer, T., Cass, M., Hodge, P., Macairan, M. L., Marks, L. S., Rittenhouse, H. (2006). APTIMA PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer. Clin. Chem. 52: 1089-1095 [Abstract] [Full Text]  
• Hamashima, C., Sobue, T., Muramatsu, Y., Saito, H., Moriyama, N., Kakizoe, T. (2006). Comparison of Observed and Expected Numbers of Detected Cancers in the Research Center for Cancer Prevention and Screening Program. Jpn J Clin Oncol 36: 301-308 [Abstract] [Full Text]  
• Carter, H. B. (2006). Assessing risk: does this patient have prostate cancer?. JNCI J Natl Cancer Inst 98: 506-507 [Full Text]  
• Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., Coltman, C. A. Jr. (2006). Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.. JNCI J Natl Cancer Inst 98: 529-534 [Abstract] [Full Text]  
• Hoffman, R. M. (2006). Viewpoint: limiting prostate cancer screening.. ANN INTERN MED 144: 438-440 [Abstract] [Full Text]  
• Catalona, W. J., Loeb, S., Han, M. (2006). Viewpoint: expanding prostate cancer screening.. ANN INTERN MED 144: 441-443 [Abstract] [Full Text]  
• Lippman, S. M., Lee, J. J. (2006). Reducing the "Risk" of Chemoprevention: Defining and Targeting High Risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.. Cancer Res. 66: 2893-2903 [Abstract] [Full Text]  
• Tan, E.M., Koziol, J. A., Kida, Y., Thorat, M. A., Badwe, R. A., Rocco, B., Djavan, B., de Cobelli, O., Wang, X., Ghosh, D., Chinnaiyan, A. M. (2005). Autoantibodies in prostate cancer.. NEJM 353: 2815-2817 [Full Text]  
• Yeh, A. H., Jeffery, P. L., Duncan, R. P., Herington, A. C., Chopin, L. K. (2005). Ghrelin and a Novel Preproghrelin Isoform Are Highly Expressed in Prostate Cancer and Ghrelin Activates Mitogen-Activated Protein Kinase in Prostate Cancer. Clin. Cancer Res. 11: 8295-8303 [Abstract] [Full Text]  
• Thompson, I. M., Tangen, C. M., Klein, E. A., Lippman, S. M. (2005). Phase III Prostate Cancer Prevention Trials: Are the Costs Justified?. JCO 23: 8161-8164 [Abstract] [Full Text]  
• Klotz, L. (2005). Active Surveillance for Prostate Cancer: For Whom?. JCO 23: 8165-8169 [Abstract] [Full Text]  
• Klein, E. A., Tangen, C. M., Goodman, P. J., Lippman, S. M., Thompson, I. M. (2005). Assessing Benefit and Risk in the Prevention of Prostate Cancer: The Prostate Cancer Prevention Trial Revisited. JCO 23: 7460-7466 [Abstract] [Full Text]  
• Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D., Mehra, R., Montie, J. E., Pienta, K. J., Sanda, M. G., Kantoff, P. W., Rubin, M. A., Wei, J. T., Ghosh, D., Chinnaiyan, A. M. (2005). Autoantibody Signatures in Prostate Cancer. NEJM 353: 1224-1235 [Abstract] [Full Text]  
• Albertsen, P. C., Hanley, J. A., Fine, J. (2005). Localized Prostate Cancer and DNA Ploidy--Reply. JAMA 294: 1207-1208 [Full Text]  
• Thompson, I. M., Canby-Hagino, E., Lucia, M. S. (2005). Stage Migration and Grade Inflation in Prostate Cancer: Will Rogers Meets Garrison Keillor. JNCI J Natl Cancer Inst 97: 1236-1237 [Full Text]  
• Saraiya, M., Kottiri, B. J., Leadbetter, S., Blackman, D., Thompson, T., McKenna, M. T., Stallings, F. L. (2005). Total and Percent Free Prostate-Specific Antigen Levels among U.S. Men, 2001-2002. Cancer Epidemiol. Biomarkers Prev. 14: 2178-2182 [Abstract] [Full Text]  
• Parsons, J. K., Carter, H. B., Platz, E. A., Wright, E. J., Landis, P., Metter, E. J. (2005). Serum Testosterone and the Risk of Prostate Cancer: Potential Implications for Testosterone Therapy. Cancer Epidemiol. Biomarkers Prev. 14: 2257-2260 [Abstract] [Full Text]  
• Welch, H. G., Schwartz, L. M., Woloshin, S. (2005). Prostate-Specific Antigen Levels in the United States: Implications of Various Definitions for Abnormal. JNCI J Natl Cancer Inst 97: 1132-1137 [Abstract] [Full Text]  
• Sheffield, J. V.L., Larson, E. B. (2005). Update in General Internal Medicine. ANN INTERN MED 143: 212-221 [Full Text]  
• Kristal, A. R., Schenk, J. M. (2005). Directions for Future Epidemiological Research in Lycopene and Prostate Cancer Risk. J. Nutr. 135: 2037S-2039S [Full Text]  
• Sharifi, N., Gulley, J. L., Dahut, W. L. (2005). Androgen Deprivation Therapy for Prostate Cancer. JAMA 294: 238-244 [Abstract] [Full Text]  
• Thompson, I. M., Ankerst, D. P., Chi, C., Lucia, M. S., Goodman, P. J., Crowley, J. J., Parnes, H. L., Coltman, C. A. Jr (2005). Operating Characteristics of Prostate-Specific Antigen in Men With an Initial PSA Level of 3.0 ng/mL or Lower. JAMA 294: 66-70 [Abstract] [Full Text]  
• Talcott, J. A. (2005). Employment After Therapy for Localized Prostate Cancer: Widening the Perspective. JNCI J Natl Cancer Inst 97: 948-949 [Full Text]  
• Bastian, P. J., Ellinger, J., Wellmann, A., Wernert, N., Heukamp, L. C., Muller, S. C., von Ruecker, A. (2005). Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene Loci. Clin. Cancer Res. 11: 4097-4106 [Abstract] [Full Text]  
• Paul, B., Dhir, R., Landsittel, D., Hitchens, M. R., Getzenberg, R. H. (2005). Detection of Prostate Cancer with a Blood-Based Assay for Early Prostate Cancer Antigen. Cancer Res. 65: 4097-4100 [Abstract] [Full Text]  
• Bradley, S. V., Oravecz-Wilson, K. I., Bougeard, G., Mizukami, I., Li, L., Munaco, A. J., Sreekumar, A., Corradetti, M. N., Chinnaiyan, A. M., Sanda, M. G., Ross, T. S. (2005). Serum Antibodies to Huntingtin Interacting Protein-1: A New Blood Test for Prostate Cancer. Cancer Res. 65: 4126-4133 [Abstract] [Full Text]  
• Albertsen, P. C., Hanley, J. A., Fine, J. (2005). 20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer. JAMA 293: 2095-2101 [Abstract] [Full Text]  
• Parnes, H. L. (2005). Prostate Cancer: Phase III Prevention Trials. aacredbook 2005: 192-195 [Full Text]  
• Grizzle, W. E., Bostwick, D. G., Burke, H., Tawfik, O. W., McGregor, D., Cohn, J., Lieberman, R. (2005). Biomarkers in Prostate Cancer. aacredbook 2005: 196-204 [Full Text]  
• Malik, G., Ward, M. D., Gupta, S. K., Trosset, M. W., Grizzle, W. E., Adam, B.-L., Diaz, J. I., Semmes, O. J. (2005). Serum Levels of an Isoform of Apolipoprotein A-II as a Potential Marker for Prostate Cancer. Clin. Cancer Res. 11: 1073-1085 [Abstract] [Full Text]  
• Lippman, S. M., Goodman, P. J., Klein, E. A., Parnes, H. L., Thompson, I. M., Kristal, A. R., Santella, R. M., Probstfield, J. L., Moinpour, C. M., Albanes, D., Taylor, P. R., Minasian, L. M., Hoque, A., Thomas, S. M., Crowley, J. J., Gaziano, J. M., Stanford, J. L., Cook, E. D., Fleshner, N. E., Lieber, M. M., Walther, P. J., Khuri, F. R., Karp, D. D., Schwartz, G. G., Ford, L. G., Coltman, C. A. (2005). Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JNCI J Natl Cancer Inst 97: 94-102 [Abstract] [Full Text]  
• Lippman, S. M., Levin, B. (2005). Cancer Prevention: Strong Science and Real Medicine. JCO 23: 249-253 [Full Text]  
• Brawley, O. W., Kramer, B. S. (2005). Cancer Screening in Theory and in Practice. JCO 23: 293-300 [Abstract] [Full Text]  
• Parnes, H. L., Thompson, I. M., Ford, L. G. (2005). Prevention of Hormone-Related Cancers: Prostate Cancer. JCO 23: 368-377 [Abstract] [Full Text]  
• Beatty, P. A., Glaser, A. I., Rocco, B., Matei, D. V., de Cobelli, O., Datta, M. W., Berman, J. J., Dhir, R. (2004). Prostate Cancer with Low PSA Levels. NEJM 351: 1802-1803 [Full Text]  
• Bermejo, C., Kristal, A. R., Zeliadt, S. B., Ramsey, S., Thompson, I. M. (2004). Localized Prostate Cancer: Quality of Life Meets Whitmore's Legacy. JNCI J Natl Cancer Inst 96: 1348-1349 [Full Text]  
• (2004). Pound of prevention, ounce of cure?. CMAJ 171: 213-213 [Full Text]  
• (2004). Vaut-il mieux guerir que prevenir?. CMAJ 171: 215-215 [Full Text]  
• (2004). Prostate Cancer Among Men with PSA ≤4.0 ng/mL. JWatch General 2004: 3-3 [Full Text]  
• Carter, H. B. (2004). Prostate Cancers in Men with Low PSA Levels -- Must We Find Them?. NEJM 350: 2292-2294 [Full Text]